San Jose, Ca., Aug 27, 2014 -- Emerald Strips, a subsidiary of Emerald Rush Holdings Inc. a biopharmaceutical company focused on R&D and commercializing novel therapeutics from its proprietary cannabinoid infused dissolving edible strips, issues the patent Xanavarin a pre-clinical testing, marketing & distribution agreement to its inventor Octavius Smith of Houston Texas.

Dr. Jonathan Palmer research director for Emerald Strips explains. "The FDA Fast Track Designation is a designation that facilitates the development, and expedites the review, of drugs treating life-threatening condition. It usually takes 60 days for a reply."

"Pure cannabinoid compounds has been delivered to our research facility where testing will begin immanently on Xanavarin," stated Dr. Palmer. "We feel Xanavarin is a promising therapy for alleviating symptoms and delaying neurodegeneration in Parkinson's disease, epilepsy, cervical dystonia, dementia," Dr. Palmer continued.

Emerald Strips has made solid progress and is at the forefront of pharmaceutical grade marijuana R&D. Their formulations will address the needs of patients choosing to use concentrated cannabis extracts. "I am proud to be a part of this team and I am very positive about our future," stated Octavius Smith, inventor of Xanavarin. "I am happy my patent was taken so serious by such a major player in "The Marijuana Industrial Complex." Marijuana pharmaceuticals are very big business, and big science. Although I am not a scientist," Smith replies jokingly, "I am big on research."

Octavius, who helped establish and consults the 55k member medical marijuana dispensary The Purple Lotus Patient Center in San Jose, mentions how things took a serious turn when his father, a 1956 Olympics boxing hopeful representing the USA and the Army, was diagnosed with CTE, pre-onset dementia due directly to his boxing career. While in Houston at his fathers house Octavius continued for over 2 years researching everything he could find to help his father. "And thanks to nature the cure was always there," Octavius concluded.

Following the completion of the toxicity and pre-clinical efficacy studies the company plans to proceed into clinical studies, and negotiations are underway to establish several commercial partnerships though out the world.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the reliance on existing regulations regarding the development of cannabis-based drugs. Emerald Strips, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Dr. Jonathan Palmer research director for Emerald Strips explains. "The FDA Fast Track Designation".
Contact Information
Author: Donna BeltonWebsite: http://www.plpcsanjose.comEmail: This email address is being protected from spambots. You need JavaScript enabled to view it.